Synopsis: The company’s subsidiary, IGI signed a $1.225 billion licensing deal with AbbVie for ISB 2001. Strong FY25 growth, global expansion, and return to profitability further boosted investor confidence. The shares of the prominent pharmaceutical company broke the...
Shares of a global research-led pharmaceutical company are in focus during Monday’s trading session, after the company received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market “Winlevi” in the United Kingdom. Price Movement With...
Search Topic or Keyword
Easiest Stock Screener Tool!
Best stock discovery tool with +130 filters, built for fundamental analysis. Profitability, Growth, Valuation, Liquidity, and many more filters. Search Stocks Industry-wise, Export Data For Offline Analysis, Customizable Filters.
